ClinicalTrials.gg
CompletedNCT07737106Updated Sep 23, 2026

Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)

A Phase 1 interventional study of Influenza Vaccine (Split Virion), Inactivated (High Dose) and Influenza Vaccine (Split Virion), Inactivated in Influenza, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Sinovac Biotech Co., Ltd · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd — 2 open to participants now, 3 under way, none of them phase 3. Influenza, Human · Sinovac Biotech Co., Ltd.

Enrollment
25th of 25
50 · median 400
Started
2025
with 1 other
Phase 1
4 of 27
1 open now
Registered
25th of 27
by date

Among the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, this one is the 25th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 25th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

This is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.

Read the detailed description

50 participants aged 60 years and older will be enrolled and randomly assigned in a 1:1 ratio to receive one dose of the investigational vaccine or the active control vaccine (Anflu®).

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 60 years and older who are in stable health condition.
  2. Participants who are fully informed and voluntarily sign the form.
  3. Participants who are willing and able to comply with all study procedures and remain contactable throughout the study.
  4. Participants who are able to provide valid legal identification.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have received a seasonal influenza vaccine within 6 months before enrollment, have received a seasonal influenza vaccine for the current influenza season, or plan to receive a seasonal influenza vaccine during the study.
  2. Participants who have had seasonal influenza within 6 months before enrollment.
  3. Participants with known severe allergy to any vaccine or vaccine component, such as urticaria, dyspnea, angioedema, or anaphylactic shock.
  4. Participants with poorly controlled chronic diseases or a history of serious diseases, including but not limited to cardiovascular diseases, such as hypertension not controlled by medication (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg measured at the study site) or coronary heart disease; metabolic diseases, such as poorly controlled diabetes; hematologic diseases; hepatic or renal diseases; digestive system diseases; respiratory system diseases; malignant tumors; a history of major organ transplantation; or any other disease or physiological condition that, in the investigator's opinion, may interfere with the study results.
  5. Participants with diseases or immunodeficiency diseases, including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, or infection.
  6. Participants with coagulation disorders, such as coagulation factor deficiency or abnormalities.
  7. Participants with current or previous severe neurological disease or psychiatric disease, or a family history of psychiatric disease.
  8. Participants with a history of long-term alcohol abuse or drug abuse.
  9. Participants with a history of Guillain-Barré syndrome (GBS).
  10. Participants who have received agents or other immunomodulatory therapy for ≥14 days within the past 6 months (prednisone ≥20 mg/day or equivalent), cytotoxic therapy, or plan to receive such therapy during the study. spray therapy for allergic rhinitis and topical corticosteroid therapy for acute uncomplicated dermatitis are excluded from this criterion.
  11. Participants who have received immunoglobulin or other blood products within 3 months before receiving the study vaccine, or plan to receive such treatment during the study.
  12. Participants who have received other drugs or vaccines within 30 days before receiving the study vaccine, or plan to receive such drugs or vaccines during the study.
  13. Participants who have received or RNA vaccines within 14 days before receiving the study vaccine.
  14. Participants who have received subunit or inactivated vaccines within 7 days before receiving the study vaccine.
  15. Participants with any acute disease, acute exacerbation of a chronic disease, or known or suspected active infection within the past 7 days.
  16. Participants with fever on the planned day of study vaccination, defined as axillary temperature >37.0°C before vaccination.
  17. Participants who, in the investigator's opinion, have any other factors that make them unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Influenza Vaccine (Split Virion), Inactivated (High Dose)

    Participants will receive one dose of Influenza Vaccine (Split Virion), Inactivated (High Dose).

    Biological: Influenza Vaccine (Split Virion), Inactivated (High Dose)

  • Active comparator
    Influenza Vaccine (Split Virion), Inactivated

    Participants will receive one dose of the active control influenza vaccine.

    Biological: Influenza Vaccine (Split Virion), Inactivated

Interventions

  • BiologicalInfluenza Vaccine (Split Virion), Inactivated (High Dose)

    A single 0.5 mL dose of the investigational high-dose split influenza virus vaccine will be administered by intramuscular (IM) injection into the deltoid muscle of the upper arm. Each dose contains 60 μg of hemagglutinin from each influenza virus strain used for the current influenza season.

  • BiologicalInfluenza Vaccine (Split Virion), Inactivated

    A single 0.5 mL dose of the active control standard-dose split influenza virus vaccine will be administered by intramuscular (IM) injection into the deltoid muscle of the upper arm. Each dose contains 15 μg of hemagglutinin from each influenza virus strain used for the current influenza season.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Reactions

    Time frame: Day 0 to Day 28 after vaccination

Secondary outcomes

  1. Incidence of adverse reactions

    Time frame: Day 0 to Day 7

  2. Incidence of serious adverse events

    Time frame: within 6 months after vaccination

  3. Seropositive Rate of HI Antibodies

    Time frame: Day 14

  4. Seroprotection Rate of HI Antibodies

    Time frame: Day 14

  5. GMT of HI Antibodies

    Time frame: Day 14

  6. GMI of HI Antibodies

    Time frame: Day 14

  7. Seropositive Rate of HI Antibodies

    Time frame: Day 28

  8. Seroprotection Rate of HI Antibodies

    Time frame: Day 28

  9. GMT of HI Antibodies

    Time frame: Day 28

  10. GMI of HI Antibodies

    Time frame: Day 28

07

Study locations

1 site
  • Urad Middle Banner Center for Disease Control and Prevention
    Bayan Nur, Inner Mongolia 015300, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Sep 2025, 0 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 0 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 30, 2026
StartActual
Aug 21, 2025
Primary completionActual
Sep 18, 2025
CompletionActual
Feb 24, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07737106
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Aug 21, 2025
Primary completion
Sep 18, 2025
Completion
Feb 24, 2026
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion